DBVTF News and Press, Dbv Techs Boulogne Bill From 03/07/23

Montrouge, France, March 7, 2023 DBV Technologies Announces First Patient Screen ed in VITESSE Phase 3 Clinical Trial in Peanut - Allergic Children 4 – 7 Years Old First patient screened at Midwest Allergy Sinus Asthma in Normal, Illino...

DBV Technologies S.A. (DBVT) Q4 2022 Results Conference Call March 02, 2023 05:00 PM ET Company Participants Anne Pollak - Head IR Daniel Tassé - CEO Sébastien Robitaille - CFO Pharis Mohideen - Chief Medical Officer Conference Call Participants ...

Montrouge, France, March 2, 2023 DBV Techn ologies a nnounces f iling of 202 2 Annual Report on Form 10-K and 202 2 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBV...

Montrouge, France, March 2, 2023 DBV Technologies Reports Full Year 2022 Financial Results and Business Update DBV completed EVOLVE, a 12-week caregiver and patient user experience study of the modified Viaskin Peanut patch in peanut-allergic children ages 4 – 11 years old ...

Montrouge, France, February 27, 2023 DBV Technologies to Report Full Year 202 2 Financial Results and Business Updates on March 2 , 202 3 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharma...

Montrouge, France, February 21, 2023 DBV Technologies to Participate in Upcoming AAAAI 2023 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation at t...

Montrouge, France, February 10, 2023 DBV Technologies t o Participate i n Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its parti...

AMF Regulated Information Montrouge, France, January 23, 2023 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, toda...

Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of Dec em ber 3 1 , 202 2 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Mark...